| ［1］ |
Osman M, Park SL, Mackay LK. Tissue⁃resident memory T （TRM ） cells: front⁃line workers of the immune system［J］. Eur J Immunol, 2023,53（11）:e2250060. DOI: 10.1002/eji.202250060.
|
| ［2］ |
Li L, Liu P, Chen C, et al. Advancements in the characterization of tissue resident memory T cells in skin disease［J］. Clin Immunol. 2022,245（12）:109183. DOI: 10.1016/j.clim.2022.109183.
|
| ［3］ |
Dong C, Lin L, Du J. Characteristics and sources of tissue⁃resident memory T cells in psoriasis relapse［J］. Curr Res Immunol, 2023,4:100067. DOI: 10.1016/j.crimmu.2023.100067.
|
| ［4］ |
Chen L, Shen Z. Tissue⁃resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders［J］. Cell Mol Immunol, 2020,17（1）:64⁃75. DOI: 10. 1038/s41423⁃019⁃0291⁃4.
|
| ［5］ |
Jan PN, Jana DA, Silvia AV, et al. CCR4 in cutaneous T⁃cell lymphoma: therapeutic targeting of a pathogenic driver［J］. European journal of immunology, 2021,51（7）:1660⁃1671.
|
| ［6］ |
McCully ML, Ladell K, Andrews R, et al. CCR8 expression defines tissue⁃resident memory T cells in human skin［J］. J Immunol, 2018,200（5）:1639⁃1650. DOI: 10.4049/jimmunol. 1701377.
|
| ［7］ |
Tokura Y, Phadungsaksawasdi P, Kurihara K, et al. Pathophysiology of skin resident memory T cells［J］. Front Immunol, 2020,11:618897. DOI: 10.3389/fimmu.2020.618897.
|
| ［8］ |
Zhu HQ, Xu QN. The roles of skin⁃resident memory T cells in dermatoses［J］. Int J Dermatol Venerol, 2019,2（1）:29⁃32. DOI:10.3760/cma.j.issn.2096⁃5540.2019.01.006.
|
| ［9］ |
甘奕传, 张三泉, 张锡宝. Treg、γδT和TRM细胞在斑块状银屑病免疫病理机制中的研究进展［J］. 中国皮肤性病学杂志, 2023,37（11）:1328⁃1333. DOI: 10.13735/j.cjdv.1001⁃7089.2021 12103.
|
| ［10］ |
Frączek A, Owczarczyk⁃Saczonek A, Placek W. The role of Trm cells in the pathogenesis of vitiligo⁃a review of the current state⁃of⁃the⁃art［J］. Int J Mol Sci, 2020,21（10）:3552. DOI: 10.3390/ijms21103552.
|
| ［11］ |
Zitti B, Hoffer E, Zheng W, et al. Human skin⁃resident CD8+ T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a［J］. Immunity, 2023,56（6）:1285⁃1302. DOI: 10.1016/j.immuni.2023.05.003.
|
| ［12］ |
Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries［J］. JID Innov, 2022,2（3）:100116. DOI: 10.1016/j.xjidi.2022.100116.
|
| ［13］ |
Kasprowicz⁃Furmańczyk M, Czerwińska J, Placek W, et al. Assessment of the tissue resident memory cells in lesional skin of patients with psoriasis and in healthy skin of healthy volunteers［J］. Int J Environ Res Public Health, 2021,18（21）:1251. DOI: 10.3390/ijerph182111251.
|
| ［14］ |
Whitley SK, Li M, Kashem SW, et al. Local IL⁃23 is required for proliferation and retention of skin⁃resident memory TH17 cells［J］. Sci Immunol, 2022,7（77）:eabq3254. DOI: 10.1126/sciimmunol.abq3254.
|
| ［15］ |
Flora A, Frew JW. A case series of early biologic therapy in guttate psoriasis: targeting resident memory T cell activity as a potential novel therapeutic modality［J］. JAAD Case Rep, 2022,24（5）:82⁃87. DOI: 10.1016/j.jdcr.2022.04.019.
|
| ［16］ |
Lu J, Huang D, Yang N, et al. Better efficacy, lower recurrence rate and decreased CD8+TRM with guselkumab treatment for generalized pustular psoriasis: a prospective cohort study from China［J］. Clin Immunol, 2024,259:109899. DOI: 10.1016/j.clim.2024.109899.
|
| ［17］ |
Boniface K, Jacquemin C, Darrigade AS, et al. Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3［J］. J Invest Dermatol, 2018,138（2）:355⁃364. DOI: 10.1016/j.jid.2017.08.038.
|
| ［18］ |
Ng CY, Chan YP, Chiu YC, et al. Targeting the elevated IFN⁃γ in vitiligo patients by human anti⁃ IFN⁃γ monoclonal antibody hampers direct cytotoxicity in melanocyte［J］. J Dermatol Sci, 2023,110（3）:78⁃88. DOI: 10.1016/j.jdermsci.2023.04.006.
|
| ［19］ |
Richmond JM, Strassner JP, Zapata L, et al. Antibody blockade of IL⁃15 signaling has the potential to durably reverse vitiligo［J］. Sci Transl Med, 2018,10（450）:7710. DOI: 10.1126/scitranslmed.aam7710.
|
| ［20］ |
Bhardwaj S, Rani S, Kumaran MS, et al. Expression of Th17⁃ and Treg⁃specific transcription factors in vitiligo patients［J］. Int J Dermatol, 2020,59（4）:474⁃481. DOI: 10.1111/ijd.14766.
|
| ［21］ |
Chen J, Wang X, Cui T, et al. Th1⁃like Treg in vitiligo: an incompetent regulator in immune tolerance［J］. J Autoimmun,2022,131:102859. DOI:10.1016/j.jaut.2022.102859.
|
| ［22］ |
Shah F, Giri PS, Bharti AH, et al. Compromised melanocyte survival due to decreased suppression of CD4+ & CD8+ resident memory T cells by impaired TRM⁃regulatory T cells in generalized vitiligo patients［J］. Exp Dermatol, 2024,33（1）:e14982. DOI: 10.1111/exd.14982.
|
| ［23］ |
Vale E, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects［J］. An Bras Dermatol, 2023,98（3）:355⁃372. DOI: 10.1016/j.abd. 2022.09.005.
|
| ［24］ |
Gu HJ, Song S, Roh JY, et al. Expression pattern of tissue⁃resident memory T cells in cutaneous lupus erythematosus［J］. Lupus, 2021,30（9）:1427⁃1437. DOI: 10.1177/09612033211017218.
|
| ［25］ |
Zhao Z, Zhu H, Li Q, et al. Skin CD4+ Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases［J］. J Autoimmun, 2022,128:102811. DOI: 10.1016/j.jaut.2022.102811.
|
| ［26］ |
Ryan GE, Harris JE, Richmond JM. Resident memory T cells in autoimmune skin diseases［J］. Front Immunol, 2021,12:652191. DOI: 10.3389/fimmu.2021.652191.
|
| ［27］ |
Zhou M, Guo C, Li X, et al. JAK/STAT signaling controls the fate of CD8+CD103+ tissue⁃resident memory T cell in lupus nephritis［J］. J Autoimmun, 2020,109:102424. DOI: 10.1016/j.jaut.2020. 102424.
|
| ［28］ |
Ishii N. Significance of anti⁃desmocollin autoantibodies in pemphigus［J］. J Dermatol, 2023,50（2）:132⁃139. DOI: 10.1111/1346⁃8138.16660.
|
| ［29］ |
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus［J］. Lancet, 2019,394（10201）:882⁃894. DOI: 10.1016/S0140⁃6736（19）31778⁃7.
|
| ［30］ |
Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid［J］. Autoimmun Rev, 2020,19（11）:102661. DOI: 10.1016/j.autrev.2020.102661.
|
| ［31］ |
Zou Y, Yuan H, Zhou S, et al. The pathogenic role of CD4+ tissue⁃resident memory T cells bearing T follicular helper⁃like phenotype in pemphigus lesions［J］. J Invest Dermatol, 2021,141（9）:2141⁃2150. DOI: 10.1016/j.jid.2021.01.030.
|
| ［32］ |
Haughton RD, Herbert SM, Ji⁃Xu A, et al. Janus kinase inhibitors for alopecia areata: a narrative review［J］. Indian J Dermatol Venereol Leprol, 2023,89（6）:799⁃806. DOI: 10.25259/IJDVL_1093_2022.
|
| ［33］ |
Axel De Greef, Romane Thirion, Pierre⁃Dominique Ghislain, et al. Real⁃life effectiveness and tolerance of baricitinib for the treatment of severe alopecia areata with 1⁃year follow⁃up data［J］. Dermatol Ther,2023,13（11）:2869⁃2877. DOI:10.1007/s13555⁃023⁃01030⁃x.
|
| ［34］ |
Malhotra K, Madke B. An updated review on current treatment of alopecia areata and newer therapeutic options［J］. Int J Trichology, 2023,15（1）:3⁃12. DOI: 10.4103/ijt.ijt_28_21.
|
| ［35］ |
刘元香, 梁源, 赵欣荣, 等. JAK抑制剂治疗儿童重症斑秃5例［J］. 中华皮肤科杂志, 2023,56（9）:849⁃852. DOI: 10.35541/cjd.20220317.
|
| ［36］ |
Del Duca E, Ruano Ruiz J, Pavel AB, et al. Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing［J］. Br J Dermatol, 2020,183（6）:1083⁃1093. DOI: 10.1111/bjd.19040.
|
| ［37］ |
Hashimoto K, Yamada Y, Fujikawa M, et al. Altered T cell subpopulations and serum anti⁃TYRP2 and tyrosinase antibodies in the acute and chronic phase of alopecia areata in the C3H/HeJ mouse model［J］. J Dermatol Sci, 2021,104（1）:21⁃29. DOI: 10. 1016/j.jdermsci.2021.09.001.
|
